What Global Stem Cells Group does

Global Stem Cells Group is a regenerative medicine consortium operating through multiple wholly-owned subsidiaries under parent Regenerative Medical Technologies Group Inc. (OTC: RMTG). Founded in 2010 by Benito Novas and headquartered in Miami, Florida, the company delivers an integrated ecosystem spanning physician education and certification (ISSCA), biologics manufacturing and product distribution (Cellgenic), a clinic network (Stem Cell Center), and patient treatment services (Cellular Hope Institute). The company operates across more than 30 countries with manufacturing operations in Cancún, Mexico producing xeno-free biologics including exosomes, mesenchymal stem cells, NK cells, allogeneic fibroblasts, peptide products, and PRP kits.

Revenue is generated through five primary streams: ISSCA physician training and certification programs, Cellgenic biologics and product sales, a Turnkey Exclusive Membership Program with six-figure upfront fees and ongoing supply agreements, an Authorized Distributor Program spanning 30+ countries, and a 2026 pipeline of private-label manufacturing. Combined Q1 2026 revenue reached $2,639,353, representing 93% year-over-year growth driven by 433% growth in ISSCA training ($772,005) and 102% growth in Cellgenic product sales ($1,267,076), yielding Q1 2026 gross profit of $1,766,491 and operating income of $229,783. The company targets licensed physicians, regenerative medicine clinics, and research institutions globally through a hybrid sales-led and channel-partner go-to-market, leveraging international conferences, regional representation agreements, and digital platforms including the ISSCA AI Clinical Intelligence Platform and ISSCA Mobile App launched June 2026.

Name

Global Stem Cells Group

Legal name

Global Stem Cells Group

Website

https://stemcellsgroup.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Global Stem Cells Group is a multi-division regenerative medicine consortium offering physician training, biologics manufacturing, and clinic network services across 30+ countries through subsidiaries ISSCA, Cellgenic, Stem Cell Center, and Cellular Hope Institute under parent RMTG.

Ownership category

akta.pro rank

Product category

Regenerative medicine biologics and physician services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

Keywords

• Regenerative medicine biologics
• Physician training certification
• Stem cell manufacturing
• Cellular therapy products
• Exosome MSC therapies

Headquarters

HQ city

Miami Lakes

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Physician Training & Certification (ISSCA): Revenue from hands-on certification programs, theoretical lectures, and live clinical practice training at international events. Q1 2026 revenue of $772,005 representing 433% year-over-year growth.
2. Biologics & Product Sales (Cellgenic): Sale of biologics including exosomes, MSCs, NK cells, allogeneic fibroblasts, peptide pens, PRP kits through authorized distributor program. Q1 2026 revenue of $1,267,076 representing 102% year-over-year growth.
3. Turnkey Membership Program: Upfront membership fees in six-figure dollar range plus ongoing exclusive supply agreements. New members receive turnkey assistance in setting up regenerative medicine clinics with continuous training and support.
4. Authorized Distributor Program: Distribution partnerships for Cellgenic products across 30+ countries, creating recurring revenue through ongoing exclusive product purchases.
5. Private-Label Manufacturing: 2026 pipeline expansion includes private-label and white-label manufacturing programs for biologic products.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Global Stem Cells Group sells regenerative medicine products and services to licensed physicians and medical institutions worldwide. Its core commercial activities are (a) Cellgenic's xeno-free biologics manufacturing and distribution of exosomes, MSCs, NK cells, allogeneic fibroblasts, peptide pens, and PRP kits; (b) ISSCA's physician training, certification, and international conferences in regenerative medicine; and (c) a turnkey Stem Cell Center clinic membership program with six-figure exclusive-territory memberships and recurring supply agreements across 30+ countries.

Product overview

Global Stem Cells Group operates as a multi-division regenerative medicine consortium combining clinical research, physician education, biologics manufacturing, and patient treatment services. The portfolio is organized around ISSCA (International Society for Stem Cell Application) for education and certification, Cellgenic for biologics manufacturing and product supply, Stem Cell Center for the physician clinic network, and Cellular Hope Institute for patient treatment services. Key products include the Cellgenic biologics line (exosomes, MSCs, NK cells, fibroblasts, peptides, PRP kits), the ISSCA AI Clinical Intelligence Platform for AI-powered clinical support, the ISSCA Mobile App for digital physician training, and the CELLGENIC Peptide Pen for peptide therapy delivery. The group maintains operations across 30+ countries with a Cancún-based manufacturing facility.

Differentiator

Problem solved

Functional benefit

Brands

• ISSCA AI: Clinical Intelligence Platform - artificial intelligence system for physicians to interpret clinical data, organize treatment workflows, and manage patient data complexity
• ISSCA Mobile App
• CELLGENIC Peptide Pen
• Exosome Flow Series
• GCell

Products and services

• ISSCA Physician Training & Certification Hands-on certification programs, theoretical lectures, and live clinical practice training delivered through international conferences and workshops for licensed physicians seeking regenerative medicine credentials. Q1 2026 revenue of $772,005 representing 433% year-over-year growth.
• Cellgenic Biologics Product Line (Exosomes, MSCs, NK Cells, Allogeneic Fibroblasts, Sterile Diluents, Lyophilized Exosomes) Xeno-free biologics manufactured in the Cancún facility and sold exclusively to authorized physicians, clinics, and research institutions. The product line includes the Exosome Flow Series (liquid exosomes in multiple concentrations), Lyophilized Exosomes (freeze-dried for topical and localized use), Umbilical Cord-Derived Mesenchymal Stem Cells (cryopreserved culture-expanded MSCs), Cellgenic NK Cells, Allogeneic Fibroblasts, and Sterile Diluents. Q1 2026 Cellgenic revenue of $1,267,076 representing 102% year-over-year growth.
• Stem Cell Center Turnkey Exclusive Membership Program Six-figure-dollar turnkey membership package that includes turnkey assistance setting up regenerative medicine clinics, exclusive territorial rights, ongoing physician training and certification, continuous clinical and marketing support, and exclusive Cellgenic supply agreements. Multi-year contracts with recurring supply purchases underpin the program.
• CELLGENIC Peptide Pen Product Line Pre-loaded peptide therapy devices containing synergistic peptide formulations targeting recovery, immune balance, and metabolic optimization, sold exclusively to physicians through the global RMTG network for clinical and wellness use.
• ISSCA AI Clinical Intelligence Platform AI-powered software platform that assists physicians in interpreting clinical data, organizing treatment workflows, and managing data complexity in regenerative and longevity medicine. Leverages millions of records from over 30 years of patient history and is being introduced across ISSCA's 30+ country physician network as part of a connected clinical ecosystem.
• ISSCA Mobile App Physician-facing mobile application providing on-demand regenerative medicine training, certification tracking, live webinars, and physician collaboration tools. Digitizes the global physician network across 30+ countries as a strategic shift from in-person-only training toward a scalable digital ecosystem model.
• Cellular Hope Institute Patient Treatment Services In-person regenerative medicine treatment service that evaluates, diagnoses, and treats patients using advanced regenerative therapies, providing a pathway for personalized treatment plans. Operates in close coordination with the Cellgenic manufacturing facility and ISSCA programs and serves as a clinical and educational anchor in Cancún for visiting physicians observing manufacturing workflows.
• GCell Adipose Stem Cell Processing System All-in-one solution for adipose stem cell processing designed to streamline adipose tissue procedures for physicians performing stem cell harvesting at the point of care.
• Cellgenic PRP Kit Platelet-rich plasma kit for regenerative medicine applications in clinical settings, designed for physician use in preparing PRP for point-of-care treatments.

Quantifiable outcome

• Q1 2026 revenue of $2,639,353 representing 93% increase year-over-year
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Dra. Patria González (Dominican Republic)coreChannel Partner/ Reseller/ Distributor · 21 October 2025Official CELLGENIC representative in Dominican Republic with partners Dr. Faddis Will and Irma Sánchez. Introduction of exosome products and MSC therapies with ISSCA 2026 event planned for Q1.
• Julius Ladeira (Brazil)coreChannel Partner/ Reseller/ Distributor · 2 October 2025Strategic representation agreement bringing full scope of GSCG divisions including ISSCA education programs and CELLGENIC biologics into Brazil healthcare market. Brazil home to 600,000+ physicians with ~50,000 engaged in regenerative practices.
• Dr. José Luis Décima (Argentina/Paraguay)coreChannel Partner/ Reseller/ Distributor · 4 August 2025Former Minister of Health for Formosa province appointed as representative for Argentina's northern region and Paraguay. Plans include new regenerative medicine center in Formosa with multidisciplinary team, training programs, and clinical care.
• Dr. Juan C. Ramos and Dr. Aleida G. Nieves (Puerto Rico)coreChannel Partner/ Reseller/ Distributor · 1 August 2025Official Global Stem Cells Group Puerto Rico representation. Puerto Rico's $4.2 billion healthcare market with U.S. territory status providing regulatory familiarity. Plans include certified training center, local distribution network, and ISSCA Puerto Rico event.
• Njinsky Medical Centre (Pakistan)coreChannel Partner/ Reseller/ Distributor · 20 May 2025Five-year exclusive distribution agreement for CELLGENIC exosome products in Pakistan. Includes development of multiple stem cell treatment centers, four physician training sessions annually, and establishment of international medical congress. Certified with ISO 9001, ISO 14644, ISO 15189, and GMP-compliant facilities.
• Cellular Hope Institute (Cancún)coreStrategic or Co-development PartnerClinical and educational center operating in close coordination with Cellgenic manufacturing facility and ISSCA. Visiting physicians observe manufacturing workflows and participate in hands-on educational sessions related to biologics handling.
• Far Eastern UniversityminorStrategic or Co-development PartnerAlliance to advance in-office stem cell procedures through academic partnership.
• Maimonides UniversityminorStrategic or Co-development PartnerJoint venture with Research Center in Tissue Engineering and Cellular Therapy for academic collaboration.

Scale indicators11 records

Recent moves13 records

Expansion highlights5 records

Direct peers

• Regenexx: Regenexx operates a global physician network offering regenerative medicine training, protocols and orthobiologics procedures. It is the closest direct peer to GSCG's combination of physician certification, biologics supply and clinic network for stem cell therapies.
• Pluristem Therapeutics: Pluristem develops placental-derived cell therapy products for multiple indications. It is a smaller cell therapy developer competing in the same regenerative biologics category as Cellgenic, with a comparable B2B/physician-focused commercialization approach in international markets.
• BioRestorative Therapies: BioRestorative Therapies develops cell-based therapies and products targeting disc/spine and metabolic indications. It is a small public regenerative-medicics peer with a similar mix of stem cell product development and physician-channel commercialization.
• InGeneron: InGeneron develops point-of-care autologous adipose-derived stem cell therapies and processing systems. It directly parallels GSCG's GCell adipose processing platform and physician-channel regenerative medicine model.

Broad incumbents

• Organogenesis: Organogenesis is an established regenerative medicine company selling biologic wound care and surgical products. It overlaps with Cellgenic in the broader regenerative biologics market and represents the type of larger incumbent GSCG competes against for hospital and physician contracts.
• Mesoblast: Mesoblast develops allogeneic cellular medicines (including MSC-based therapies) for inflammatory and cardiovascular conditions. It is a publicly listed stem cell therapy developer comparable in therapeutic area to GSCG's MSC and exosome portfolio, but at a more advanced clinical stage.
• Smith+Nephew: Smith+Nephew is a global medical device company with a sizeable orthobiologics franchise (including regenerative cartilage and sports medicine products). It competes for the same physician customers and regenerative procedure volumes that GSCG targets through its clinic network.

Emerging players

• Caladrius Biosciences: Caladrius Biosciences is a clinical-stage cell therapy company developing CD34+ and other cell-based treatments. It is comparable to GSCG in therapeutic focus on regenerative cell therapies but operates at a more advanced regulatory and clinical stage.
• BrainStorm Cell Therapeutics: BrainStorm develops autologous cell therapies (NurOwn) for neurodegenerative diseases. It is relevant as a peer in adult stem cell therapeutic development and shares the same regulatory and reimbursement pressures facing GSCG's cell-based products.
• CelProgen: CelProgen supplies stem cell products, media, and research services to researchers and clinics. It competes with Cellgenic in the upstream supply of MSCs, exosomes and ancillary cell-processing materials for regenerative medicine practitioners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCR1FwbKlJy2WnH66dgMVyTA
• Facebookfacebook.com/366985720045080
• Instagraminstagram.com/issca.us
• Xx.com/stemcellgroupus
• LinkedInlinkedin.com/company/global-stem-cells-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Stem Cells Group